Ocugen Inc. stock rises 2.41 percent, ending five-day losing streak

9 articles · Updated · MarketWatch · Apr 27

Shares closed at $1.70 on Monday, outperforming the S&P 500 and Dow Jones in a mixed session.
Trading volume was 4.5 million, significantly below the 50-day average of 8.7 million shares.
Despite the gain, Ocugen remains 37.61% below its 52-week high of $2.73 reached in March 2026.

Is Ocugen's latest stock rally a dead cat bounce or the beginning of a major turnaround?

With a 'going concern' warning, can Ocugen's cash last long enough for its gene therapies to succeed?

Will a reverse stock split save Ocugen or is it a final warning sign for investors?

With only one FDA approval in its field since 2017, what makes Ocugen think it can beat the odds?

Could Ocugen's 'gene-agnostic' therapy truly be a breakthrough cure for a complex form of blindness?